About Careers MedBlog Contact us

Side effect(s) of Eculizumab

Read the side effects of Eculizumab as described in the medical literature. In case of any doubt consult your doctor or pharmacist.

Infections: Meningococcal infections with symptoms of headache, fever, nausea, vomiting, stiff neck or stiff back, rash, muscle aches, flu-like syndrome and /or increased sensitivity of eyes to light; upper respiratory tract infections and urinary tract infections.

Gastrointestinal: Nausea, vomiting, stomach pain, diarrhea, constipation

Allergy: Allergy to the drug may include a severe anaphylactic reaction.

Central nervous system: Headache, difficulty in falling asleep

Muscular: Muscle, back, limb and/or joint pain.

Respiratory: Sore throat, cough, sinusitis, runny nose.

Cardiovascular: High blood pressure, fluid accumulation, increase in heart rate, low blood pressure.

Kidney: Reduced kidney function

Blood: Anemia, low white blood cell count, low blood potassium levels. Excessive clotting of blood may occur after stopping treatment in patients with atypical hemolytic uremic syndrome

Skin: Rash, itching.

Other Precautions : Avoid excess dosage. Discontinue the drug if the patient suffers from severe meningococcal infections.

Drug Name : Eculizumab

Eculizumab(Soliris) generic Eculizumab is a monoclonal antibody, which is prescribed for two conditions: Paroxysmal nocturnal hemoglobinuria (PNH) in which red blood cells (RBCs) are broken down resulting in anemia and decreased oxygen supply to the body. Atypical hemolytic uremic syndrome (aHUS), where small blood clots are formed which block blood supply and cause damage to kidney and other organs. Eculizumab is an orphan drug since it is used only for the above rare conditions. It acts by blocking a part of the immune system called the complement system. In paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, the complement system acts abnormally and destroys the red blood cells and increases the risk of blood clots respectively.
More Info about Eculizumab

International : 


Recommended Reading
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close